Metabolic changes in the knockout mouse for Canavan's disease: Implications for patients with Canavan's disease

Sankar Surendran, Kimberlee M. Matalon, Sylvia Szucs, Stephen K. Trying, Reuben Matalon

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Canavan's disease is an autosomal recessive disorder caused by aspartoacylase deficiency, which leads to accumulation of N-acetylaspartic acid in the brain and blood and an elevated level of N-acetylaspartic acid in the urine. The brain of patients with Canavan's disease shows spongy degeneration. How the enzyme deficiency and elevated N-acetylaspartic acid cause the pathophysiology observed in Canavan's disease is not obvious. The creation of a knockout mouse for Canavan's disease is being used as a tool to investigate metabolic pathways in the mouse and correlate them with the patients with Canavan's disease. The level of glutamate is lower in the knockout mouse brain than in the wild-type mouse brain, similar to what we have found in children with Canavan's disease, and so are the levels of γ-aminobutyric acid (GABA). The level of aspartate is higher in the Canavan's disease mouse brain. The activity of aspartate aminotransferase, an enzyme involved in the malate-aspartate shuttle, is lower in the Canavan's disease mouse brain. The lower weight of the Canavan's disease mouse was in direct proportion to low total-body fat and bone mineral density. These changes might be similar to what is seen in patients with Canavan's disease and could have therapeutic implications.

Original languageEnglish (US)
Pages (from-to)611-615
Number of pages5
JournalJournal of Child Neurology
Volume18
Issue number9
StatePublished - Sep 1 2003

Fingerprint

Canavan Disease
Knockout Mice
Brain
Aspartic Acid
Aminobutyrates
Enzymes
Aspartate Aminotransferases
Metabolic Networks and Pathways
Bone Density
gamma-Aminobutyric Acid

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health

Cite this

Metabolic changes in the knockout mouse for Canavan's disease : Implications for patients with Canavan's disease. / Surendran, Sankar; Matalon, Kimberlee M.; Szucs, Sylvia; Trying, Stephen K.; Matalon, Reuben.

In: Journal of Child Neurology, Vol. 18, No. 9, 01.09.2003, p. 611-615.

Research output: Contribution to journalArticle

Surendran, Sankar ; Matalon, Kimberlee M. ; Szucs, Sylvia ; Trying, Stephen K. ; Matalon, Reuben. / Metabolic changes in the knockout mouse for Canavan's disease : Implications for patients with Canavan's disease. In: Journal of Child Neurology. 2003 ; Vol. 18, No. 9. pp. 611-615.
@article{628f85d547fe4387935ca9b8448e1de3,
title = "Metabolic changes in the knockout mouse for Canavan's disease: Implications for patients with Canavan's disease",
abstract = "Canavan's disease is an autosomal recessive disorder caused by aspartoacylase deficiency, which leads to accumulation of N-acetylaspartic acid in the brain and blood and an elevated level of N-acetylaspartic acid in the urine. The brain of patients with Canavan's disease shows spongy degeneration. How the enzyme deficiency and elevated N-acetylaspartic acid cause the pathophysiology observed in Canavan's disease is not obvious. The creation of a knockout mouse for Canavan's disease is being used as a tool to investigate metabolic pathways in the mouse and correlate them with the patients with Canavan's disease. The level of glutamate is lower in the knockout mouse brain than in the wild-type mouse brain, similar to what we have found in children with Canavan's disease, and so are the levels of γ-aminobutyric acid (GABA). The level of aspartate is higher in the Canavan's disease mouse brain. The activity of aspartate aminotransferase, an enzyme involved in the malate-aspartate shuttle, is lower in the Canavan's disease mouse brain. The lower weight of the Canavan's disease mouse was in direct proportion to low total-body fat and bone mineral density. These changes might be similar to what is seen in patients with Canavan's disease and could have therapeutic implications.",
author = "Sankar Surendran and Matalon, {Kimberlee M.} and Sylvia Szucs and Trying, {Stephen K.} and Reuben Matalon",
year = "2003",
month = "9",
day = "1",
language = "English (US)",
volume = "18",
pages = "611--615",
journal = "Journal of Child Neurology",
issn = "0883-0738",
publisher = "SAGE Publications Inc.",
number = "9",

}

TY - JOUR

T1 - Metabolic changes in the knockout mouse for Canavan's disease

T2 - Implications for patients with Canavan's disease

AU - Surendran, Sankar

AU - Matalon, Kimberlee M.

AU - Szucs, Sylvia

AU - Trying, Stephen K.

AU - Matalon, Reuben

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Canavan's disease is an autosomal recessive disorder caused by aspartoacylase deficiency, which leads to accumulation of N-acetylaspartic acid in the brain and blood and an elevated level of N-acetylaspartic acid in the urine. The brain of patients with Canavan's disease shows spongy degeneration. How the enzyme deficiency and elevated N-acetylaspartic acid cause the pathophysiology observed in Canavan's disease is not obvious. The creation of a knockout mouse for Canavan's disease is being used as a tool to investigate metabolic pathways in the mouse and correlate them with the patients with Canavan's disease. The level of glutamate is lower in the knockout mouse brain than in the wild-type mouse brain, similar to what we have found in children with Canavan's disease, and so are the levels of γ-aminobutyric acid (GABA). The level of aspartate is higher in the Canavan's disease mouse brain. The activity of aspartate aminotransferase, an enzyme involved in the malate-aspartate shuttle, is lower in the Canavan's disease mouse brain. The lower weight of the Canavan's disease mouse was in direct proportion to low total-body fat and bone mineral density. These changes might be similar to what is seen in patients with Canavan's disease and could have therapeutic implications.

AB - Canavan's disease is an autosomal recessive disorder caused by aspartoacylase deficiency, which leads to accumulation of N-acetylaspartic acid in the brain and blood and an elevated level of N-acetylaspartic acid in the urine. The brain of patients with Canavan's disease shows spongy degeneration. How the enzyme deficiency and elevated N-acetylaspartic acid cause the pathophysiology observed in Canavan's disease is not obvious. The creation of a knockout mouse for Canavan's disease is being used as a tool to investigate metabolic pathways in the mouse and correlate them with the patients with Canavan's disease. The level of glutamate is lower in the knockout mouse brain than in the wild-type mouse brain, similar to what we have found in children with Canavan's disease, and so are the levels of γ-aminobutyric acid (GABA). The level of aspartate is higher in the Canavan's disease mouse brain. The activity of aspartate aminotransferase, an enzyme involved in the malate-aspartate shuttle, is lower in the Canavan's disease mouse brain. The lower weight of the Canavan's disease mouse was in direct proportion to low total-body fat and bone mineral density. These changes might be similar to what is seen in patients with Canavan's disease and could have therapeutic implications.

UR - http://www.scopus.com/inward/record.url?scp=0141962686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141962686&partnerID=8YFLogxK

M3 - Article

C2 - 14572139

AN - SCOPUS:0141962686

VL - 18

SP - 611

EP - 615

JO - Journal of Child Neurology

JF - Journal of Child Neurology

SN - 0883-0738

IS - 9

ER -